Finding: A combination of immune checkpoint blockade and targeted therapies that block normal dna damage repair (ddr) achieved significant tumor regression in mouse models of small cell lung cancer (sclc), suggesting a promising new approach for treating patients with this aggressive cancer.
Certainty (1-5): 4.5